S-1/A: BioVie Inc. Launches $13.5M Offering Amidst Clinical Hurdles

BioVie Inc. is offering 1.98 million units of common stock and warrants to raise $13.5 million, while navigating clinical trial challenges and ongoing litigation.

Summary

• BioVie Inc. is conducting a firm commitment underwritten offering of 1,986,754 units, each consisting of one share of Class A Common Stock and one warrant, at an assumed public offering price of $7.55 per unit.
• The company is also offering 1,986,754 pre-funded units to purchasers whose beneficial ownership would exceed 4.99% (or 9.99%) of outstanding common stock, with each pre-funded unit priced at the unit price minus $0.0001.
• Warrants will have an exercise price of $9.4375 and expire five years from issuance, while pre-funded warrants are immediately exercisable at $0.0001.
• Net proceeds from the offering are estimated to be approximately $13.5 million, or $15.6 million if the underwriters' over-allotment option is fully exercised, intended for working capital and general corporate purposes.
• A 1-for-10 reverse stock split became effective on July 7, 2025, as approved by stockholders on June 23, 2025, and the Board on June 26, 2025.
• The company reported a net loss of approximately $2.8 million for the three months ended March 31, 2025, a significant reduction from $8.1 million for the same period in 2024.
• For the nine months ended March 31, 2025, the net loss was approximately $14.1 million, down from $27.2 million in the prior year period.
• Research and development expenses decreased by $4.4 million to $1.3 million for the three months ended March 31, 2025, and by $13.0 million to $8.0 million for the nine months ended March 31, 2025, primarily due to clinical trial completions and a reduction in force.
• As of March 31, 2025, the company had working capital of approximately $21.2 million and cash and cash equivalents totaling approximately $23.2 million.
• The company received a $13.1 million clinical trial grant from the U.S. Department of Defense in April 2024 for its Long COVID program, with approximately $2.9 million reimbursed for trial costs as of April 2025.
• A securities class action lawsuit filed in January 2024, alleging misrepresentations related to the Phase 3 AD study, had its motion to dismiss denied on March 27, 2025, allowing the case to proceed to fact discovery.

Sentiment

Score: 3

Explanation: The company is actively pursuing multiple clinical programs with some promising early-stage data and has secured significant grant funding. However, it faces substantial financial challenges, including recurring losses, a 'going concern' warning, and the need for continuous capital raises. The integrity issues in the AD Phase 3 trial and ongoing litigation add significant uncertainty and risk, outweighing the positive clinical progress and funding.

Positives

• The company secured a significant $13.1 million clinical trial grant from the U.S. Department of Defense for its Long COVID program, providing non-dilutive funding.
• Net loss significantly decreased to $2.8 million for the three months ended March 31, 2025, compared to $8.1 million in the prior year, and to $14.1 million for the nine months ended March 31, 2025, compared to $27.2 million.
• Research and development expenses saw substantial reductions due to the completion of prior clinical trials and operational efficiencies.
• The company successfully paid off its $15 million loan payable in full on December 1, 2024, eliminating associated interest expenses and releasing liens on assets.
• Positive Phase 2 data for bezisterim in Parkinson's Disease showed significant improvements in morning on symptoms and motor control, with a new Phase 2b study for new onset PD commencing in April 2025.
• BIV201's Phase 2 study for refractory ascites showed promising results, with patients experiencing a 53% reduction in ascites fluid, sustained at 43% for three months.
• BIV201 has FDA Fast Track and Orphan Drug designations for ascites and hepatorenal syndrome, indicating recognition of unmet medical need.
• The proprietary liquid formulation of BIV201 offers a key product differentiation with room temperature stability for up to two years, unlike competitors' refrigerated powder versions.

Negatives

• The Phase 3 Alzheimer's Disease clinical trial for bezisterim was underpowered for its primary endpoints due to significant protocol deviations and cGCP violations at 15 study sites, leading to patient exclusions and referral to the FDA Office of Scientific Investigations.
• The company has no products approved for commercial sale and has never generated any revenues, with no revenues expected in the foreseeable future.
• The company's financial statements include an explanatory paragraph about substantial doubt concerning its ability to continue as a going concern due to recurring losses and negative cash flows.
• The company is currently subject to securities class action litigation and two shareholder derivative lawsuits, which will require significant management time, attention, and legal expenses, with a $2 million deductible on insurance coverage.
• The current offering will result in immediate and substantial dilution of $(1.50) per share to new investors, and future equity offerings or exercise of outstanding options/warrants could cause further dilution.
• The company's stock price is and may continue to be volatile, and there is a risk that Nasdaq may seek to delist the common stock if the offering does not qualify as a public offering under their stockholder approval rule.
• There is no established public trading market for the Pre-funded Warrants or Warrants being offered, and the company does not expect a market to develop for the Pre-funded Warrants.
• The 1-for-10 reverse stock split has caused and could further cause the stock price to decline relative to its value before the split and decrease the liquidity of shares.

Risks

• Reliance on third-party contractors for clinical trials, with risks of non-compliance, missed deadlines, and data integrity issues (e.g., cGCP violations in AD trial).
• High uncertainty in biopharmaceutical product development, with product candidates potentially failing to reach the market due to ineffectiveness, harmful side effects, or regulatory hurdles.
• Concentration of cash assets in certain financial institutions in excess of federally insured levels, posing a risk in case of bank failures or liquidity concerns.
• Ongoing securities class action litigation and shareholder derivative lawsuits could result in substantial damages, fines, and diversion of management resources.
• The company has no approved products or revenues and may never achieve profitability, which could lead to cessation of operations.
• Need to raise substantial additional capital in the future to fund operations, which may not be available on acceptable terms or at all, potentially leading to delays or termination of programs.
• Limited experience in drug development and manufacturing, relying heavily on third-party contract manufacturing organizations (CMOs) and facing risks of non-compliance with cGMP regulations.
• Intense competition in the biotechnology and biopharmaceutical industries from companies with substantially greater resources.
• Inability to obtain or protect intellectual property rights, or challenges to existing patents, could harm competitive position and commercialization efforts.
• Potential conflicts of interest among officers, directors, and stockholders due to their involvement in other ventures or competing drug development.
• The company's status as a smaller reporting company may make its stock less attractive to potential investors.
• The authorization to issue blank check preferred stock without stockholder approval could adversely impact the rights of common stockholders.
• Anti-takeover provisions in corporate documents and Nevada law might discourage or delay changes in control or management.

Future Outlook

The company is finalizing the protocol design for a Phase 3 study of BIV201 for liver cirrhosis and ascites, focusing on a composite primary endpoint of complications and disease progression. For Alzheimer's Disease, the company is considering either continuing to enroll patients in the existing Phase 3 trial using an adaptive feature or designing a new Phase 3 study for bezisterim. New Phase 2b studies for Parkinson's Disease and Long COVID have commenced in April and May 2025, respectively. The company expects to finance future cash needs through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements, as it does not anticipate generating revenues in the foreseeable future.

Management Comments

• Management believes bezisterim may offer clinical improvements in several disease indications, including PD, AD, and long COVID, by binding to ERK and selectively modulating NFB activation and TNFproduction without interfering with homeostatic functions.
• Management believes BIV201 (continuous infusion terlipressin) has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis.
• Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.
• Management believes the claims in the securities class action and derivative lawsuits are without merit and intends to defend vigorously against them.

Industry Context

BioVie operates in the highly competitive biopharmaceutical industry, characterized by rapid technological developments and substantial resources from larger competitors like Biogen and Eli Lilly in neurodegenerative diseases. The company is targeting significant unmet medical needs in Alzheimer's Disease (estimated 6 million Americans), Parkinson's Disease (estimated 1 million Americans), and Long COVID (approximately 20 million U.S. adults, with an estimated $3.7 trillion economic impact and no proven therapies). In liver disease, specifically ascites, there are no FDA-approved drugs, presenting a potentially addressable market exceeding $650 million, though other companies like Ocelot Bio are developing therapies for severe complications of advanced liver cirrhosis.

Comparison to Industry Standards

• BioVie's bezisterim is positioned as a novel approach to treating neurodegenerative disorders by inhibiting inflammation-driven insulin resistance, differentiating it from current symptomatic relief therapies for Parkinson's Disease and existing AD treatments.
• BIV201's proprietary room temperature stable liquid formulation in a pre-filled syringe offers a significant convenience and potential safety advantage over other terlipressin products globally, which typically require refrigeration and reconstitution from powder.
• While other companies like Mallinckrodt and Ferring Pharmaceuticals have received Orphan Drug designations for terlipressin for different indications (Hepatorenal Syndrome Type 1, bleeding esophageal varices), BioVie's BIV201 has Orphan Drug designation specifically for ascites (due to all etiologies except cancer), targeting a distinct unmet need.
• The company's reliance on third-party CROs and clinical trial sites, as evidenced by the cGCP violations in the AD trial, highlights a common industry challenge in maintaining oversight and data integrity, which can lead to delays and underpowered studies, unlike more established pharmaceutical companies with extensive internal clinical operations.

Management Changes

Corporate Governance

Legal Proceedings

• A purported shareholder class action complaint, Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, was filed on January 19, 2024, in the U.S. District Court for the District of Nevada, alleging material misrepresentations and/or omissions related to the NM101 Phase 3 study and trial of bezisterim in mild to moderate probable Alzheimer's Disease.
• A second, related putative securities class action, Way v. BioVie Inc. et al., No. 2:24-cv-00361, was filed on February 22, 2024, and consolidated with the Olmstead action on April 15, 2024.
• On June 21, 2024, the lead plaintiff filed an amended complaint, seeking unspecified monetary damages and costs.
• The defendants' motion to dismiss the amended complaint was denied on March 27, 2025, allowing the case to proceed to fact discovery.
• A shareholder derivative lawsuit, Andrew Hulm, was filed on December 30, 2024, in the U.S. District Court for the District of Nevada, alleging breach of fiduciary duties by certain current and former officers and directors.
• A second shareholder derivative lawsuit, William Settel, was filed on April 28, 2025, in the U.S. District Court for the District of Nevada, asserting similar claims as the Hulm action.
• The company believes the claims are without merit and intends to defend vigorously, but the outcome is uncertain and could result in substantial costs and diversion of management time.
• Insurance coverage for these actions is subject to a $2 million deductible, meaning the company is responsible for the first $2 million of loss, including defense costs and damages.

Related Party Transactions

• The company acquired biopharmaceutical assets, including NE3107 (bezisterim), from NeurMedix, Inc., a privately held clinical-stage pharmaceutical company and a related party, in June 2021.
• On July 15, 2022, the company entered into a securities purchase agreement with Acuitas Group Holdings, LLC, the company's largest stockholder, for a private placement of common stock and warrants. The warrants included a down round feature that reduced their exercise price, resulting in deemed dividends of $325,041 for the three months ended September 30, 2024, and $44,424 for the three months ended December 31, 2024.
• The company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc., with BioVie assuming a 5.0% royalty on net sales pursuant to a separation agreement.
• A Director of the Company was paid $50,000 for consulting services during the nine months ended March 31, 2025.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution from the current offering, and further dilution is likely from future equity raises and the exercise of outstanding options and warrants.
• The company's 'going concern' warning and recurring losses pose a significant risk to shareholder investment, potentially leading to a complete loss.
• The ongoing securities class action and derivative litigation could result in substantial financial penalties and negatively impact the company's stock price and reputation, affecting shareholders.
• Employees may face continued uncertainty due to the company's financial condition and the 'reduction in force' that occurred in December 2023.
• Future patients could benefit from the successful development and commercialization of novel drug therapies for neurological disorders (AD, PD, Long COVID) and advanced liver disease (ascites), addressing significant unmet medical needs.
• Creditors, particularly those who held the recently repaid loan, have seen their obligations satisfied, but future lenders will assess the company's high-risk profile and 'going concern' status.
• Third-party contractors, including CROs and manufacturers, are critical to the company's operations, and any failures or non-compliance could impact the company's ability to advance its product candidates, affecting its business partners.

Next Steps

• Finalize the protocol design for the Phase 3 study of BIV201 for cirrhosis and ascites.
• Determine whether to employ the adaptive trial feature to continue enrolling patients for the bezisterim AD study or design a new Phase 3 study.
• Continue the new Phase 2b study of bezisterim for new onset Parkinson's Disease.
• Continue the Phase 2 ADDRESS-LC study of bezisterim for Long COVID neurological symptoms.
• Defend vigorously against the pending securities class action and shareholder derivative lawsuits.
• Seek additional financing through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements to fund ongoing operations and development.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, marked by recurring significant losses, a 'going concern' warning from its auditors, and a stated need for 'substantial additional capital' despite recent raises. The integrity issues and underpowered results of the Phase 3 Alzheimer's trial for its lead candidate, bezisterim, are a major setback, casting doubt on its most advanced program. Furthermore, the company is embroiled in multiple securities litigations, which will incur significant costs and management distraction. While there are early-stage positive signals for other programs (PD, Long COVID, BIV201), these are far from commercialization and do not offset the immediate and severe financial and operational risks. The current offering, while providing short-term liquidity, comes with significant dilution, and the recent reverse stock split has already negatively impacted share value and liquidity. Given the high degree of uncertainty, substantial financial risk, and ongoing legal and clinical challenges, a seasoned investor would likely view this as a 'strong sell' due to the high probability of further value erosion.

Keywords

Biopharmaceutical, Clinical-stage, Drug development, Alzheimer's Disease, Parkinson's Disease, Long COVID, Liver cirrhosis, Ascites, Bezisterim, NE3107, BIV201, Terlipressin, SEC filing, S-1/A, Public offering, Warrants, Pre-funded warrants, Capital raise, Clinical trials, FDA, Orphan Drug, Fast Track, Intellectual property, Litigation, Reverse stock split, Going concern, Dilution